Furthermore, BAR502, a dual agonist of FXR and TGR5, reversed high-fat diet (HFD)- or carbon tetrachloride (CCL4)-induced hepatic fibrosis in mice by upregulating the expression of SHP and FGF15 and attenuating bile acid synthesis (Carino et al., 2017). Here, NR1H4 is linked to Hepatic fibrosis.